DiaMedica Therapeutics (NASDAQ:DMAC) Earns Buy Rating from Analysts at Craig Hallum

Equities researchers at Craig Hallum assumed coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a report released on Wednesday, StockNewsAPI reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price objective would indicate a potential upside of 226.53% from the stock’s previous close.

Separately, Oppenheimer reissued an “outperform” rating and set a $6.00 price target (down from $7.00) on shares of DiaMedica Therapeutics in a research report on Thursday, March 21st.

DiaMedica Therapeutics Trading Up 1.2 %

Shares of NASDAQ:DMAC traded up $0.03 during trading on Wednesday, reaching $2.45. The company had a trading volume of 1,972 shares, compared to its average volume of 41,261. The company has a fifty day moving average of $2.81 and a two-hundred day moving average of $2.70. The stock has a market capitalization of $93.00 million, a P/E ratio of -3.90 and a beta of 1.69. DiaMedica Therapeutics has a 12 month low of $1.50 and a 12 month high of $4.75.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). As a group, equities research analysts predict that DiaMedica Therapeutics will post -0.69 earnings per share for the current year.

Institutional Trading of DiaMedica Therapeutics

Large investors have recently made changes to their positions in the stock. Avantax Advisory Services Inc. purchased a new position in shares of DiaMedica Therapeutics in the fourth quarter worth approximately $36,000. Stonebridge Capital Advisors LLC purchased a new position in shares of DiaMedica Therapeutics in the third quarter worth approximately $52,000. Finally, Paragon Associates & Paragon Associates II Joint Venture lifted its holdings in DiaMedica Therapeutics by 6.4% during the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after purchasing an additional 30,000 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.